BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 1524038)

  • 1. A phase II trial of cyclophosphamide, doxorubicin, and cisplatin in advanced breast cancer.
    Kochupillai V; Gupta P; Misra A
    Am J Clin Oncol; 1992 Oct; 15(5):388-91. PubMed ID: 1524038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two sequential studies for primary peritoneal carcinoma: induction with weekly cisplatin followed by either cisplatin-doxorubicin-cyclophosphamide or paclitaxel-cisplatin.
    Piver MS; Eltabbakh GH; Hempling RE; Recio FO; Blumenson LE
    Gynecol Oncol; 1997 Nov; 67(2):141-6. PubMed ID: 9367697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
    Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL
    Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective, randomized Phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma.
    Blajman C; Balbiani L; Block J; Coppola F; Chacon R; Fein L; Bonicatto S; Alvarez A; Schmilovich A; Delgado FM
    Cancer; 1999 Mar; 85(5):1091-7. PubMed ID: 10091793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclophosphamide, epirubicin and cisplatin (CEP) in advanced breast cancer: preliminary results.
    Zaniboni A; Marpicati P; Simoncini E; Gorni F; Ferrari V; Raffaglio E; Garattini MP; Marini G
    Anticancer Res; 1987; 7(4B):813-5. PubMed ID: 3479042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Combination chemo-endocrine therapy of metastatic and stage IV breast cancer with cyclophosphamide, adriamycin, prednisolone and tamoxifen (CAPT)--with special reference to management of brain and liver metastasis].
    Nakamura Y; Kawaguchi M; Hata A; Watanabe H; Ueki Y; Oribe T; Koba F; Takamuku K
    Gan To Kagaku Ryoho; 1989 Feb; 16(2):243-50. PubMed ID: 2919892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of a combination of vinorelbine, cyclophosphamide and 5-fluorouracil in the treatment of advanced breast cancer.
    Ardavanis A; Extra JM; Espié M; Cuvier C; Marty M
    In Vivo; 1998; 12(5):559-62. PubMed ID: 9827368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study.
    Hong RL; Sheen TS; Ko JY; Hsu MM; Wang CC; Ting LL
    Br J Cancer; 1999 Aug; 80(12):1962-7. PubMed ID: 10471046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.
    Bontenbal M; Creemers GJ; Braun HJ; de Boer AC; Janssen JT; Leys RB; Ruit JB; Goey SH; van der Velden PC; Kerkhofs LG; Schothorst KL; Schmitz PI; Bokma HJ; Verweij J; Seynaeve C;
    J Clin Oncol; 2005 Oct; 23(28):7081-8. PubMed ID: 16192591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A comparative study of 4 sequential first-line chemotherapy protocols in locally advanced breast cancer].
    Ferrero JM; Namer M; Dufour JF; Largillier R; Creisson A; Teissier E; Machiavello JC; Lallement M; Monticelli J; Abbes M
    Bull Cancer; 1997 Jan; 84(1):10-6. PubMed ID: 9180853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of cyclophosphamide, doxorubicin, and cisplatin (CAP) versus amsacrine in patients with transitional cell carcinoma of the urinary bladder: a Southwest Oncology Group study.
    Al-Sarraf M; Frank J; Smith JA; O'Bryan RM; Costanzi JJ; Stephens RL; Caraveo J; Crawford ED
    Cancer Treat Rep; 1985 Feb; 69(2):189-94. PubMed ID: 2578880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin versus mitomycin versus doxorubicin plus mitomycin in advanced breast cancer: a randomized study.
    Andersson M; Daugaard S; von der Maase H; Mouridsen HT
    Cancer Treat Rep; 1986 Oct; 70(10):1181-6. PubMed ID: 3530444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy.
    Er O; Frye DK; Kau SW; Broglio K; Valero V; Hortobagyi GN; Arun B
    Cancer J; 2008; 14(1):62-8. PubMed ID: 18303485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by age.
    Antman K; Ayash L; Elias A; Wheeler C; Schwartz G; Mazanet R; Tepler I; Schnipper LE; Frei E
    J Natl Cancer Inst Monogr; 1994; (16):91-4. PubMed ID: 7528031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAP (cyclophosphamide, adriamycin, cisplatinum) in the treatment of advanced breast cancer.
    Mechl Z; Sopková B
    Neoplasma; 1984; 31(4):431-5. PubMed ID: 6547999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.